Your browser doesn't support javascript.
loading
External Beam Accelerated Partial Breast Irradiation in Early Breast Cancer and the Risk for Radiogenic Pneumonitis.
Ott, Oliver J; Stillkrieg, Wilhelm; Lambrecht, Ulrike; Sauer, Tim-Oliver; Schweizer, Claudia; Lamrani, Allison; Strnad, Vratislav; Hack, Carolin C; Beckmann, Matthias W; Uder, Michael; Fietkau, Rainer; Distel, Luitpold.
Afiliação
  • Ott OJ; Department of Radiation Oncology, Universitätsklinikum Erlangen, 91054 Erlangen, Germany.
  • Stillkrieg W; Comprehensive Cancer Center Erlangen-EMN, 91054 Erlangen, Germany.
  • Lambrecht U; Department of Radiation Oncology, Universitätsklinikum Erlangen, 91054 Erlangen, Germany.
  • Sauer TO; Comprehensive Cancer Center Erlangen-EMN, 91054 Erlangen, Germany.
  • Schweizer C; Department of Radiation Oncology, Universitätsklinikum Erlangen, 91054 Erlangen, Germany.
  • Lamrani A; Comprehensive Cancer Center Erlangen-EMN, 91054 Erlangen, Germany.
  • Strnad V; Department of Radiation Oncology, Universitätsklinikum Erlangen, 91054 Erlangen, Germany.
  • Hack CC; Comprehensive Cancer Center Erlangen-EMN, 91054 Erlangen, Germany.
  • Beckmann MW; Department of Radiation Oncology, Universitätsklinikum Erlangen, 91054 Erlangen, Germany.
  • Uder M; Comprehensive Cancer Center Erlangen-EMN, 91054 Erlangen, Germany.
  • Fietkau R; Department of Radiation Oncology, Universitätsklinikum Erlangen, 91054 Erlangen, Germany.
  • Distel L; Comprehensive Cancer Center Erlangen-EMN, 91054 Erlangen, Germany.
Cancers (Basel) ; 14(14)2022 Jul 20.
Article em En | MEDLINE | ID: mdl-35884579
In order to evaluate the risk for radiation-associated symptomatic pneumonitis in a prospective external beam accelerated partial breast irradiation (APBI) trial, between 2011 and 2021, 170 patients with early stage breast cancer were enclosed in the trial. Patients were eligible for study participation if they had a histologically confirmed breast cancer or an exclusive ductal carcinoma in situ (DCIS), a tumor size ≤3 cm, free safety margins ≥2 mm, no involved axillary lymph nodes, tumor bed clips, and were ≥50 years old. Patients received APBI with 38 Gy with 10 fractions in 10 consecutive working days. The trial was registered at the German Clinical Trials Registry, DRKS-ID: DRKS00004417. Median follow-up was 56 (1−129) months. Ipsilateral lung MLD, V20, and V30 were 4.3 ± 1.4 Gy, 3.0 ± 2.0%, and 1.0 ± 1.0%, respectively. Radiogenic pneumonitis grade 2 appeared in 1/170 (0.6%) patients two months after radiotherapy. Ipsilateral MLD, V20, and V30 were 6.1 Gy, 7, and 3% in this patient. Additionally, individual radiosensitivity was increased in this specific patient. Compared to WBI, APBI leads to lower lung doses. Using APBI, the risk of symptomatic radiogenic pneumonitis is very low and may be limited, with an ipsilateral V20 < 3% to very exceptional cases associated with innate risk factors with an increased radiation susceptibility.
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2022 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2022 Tipo de documento: Article